

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 August 2020 (06.08.2020)



(10) International Publication Number
WO 2020/160560 A3

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 16/30 (2006.01)
A61K 39/395 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2020/016459

(22) International Filing Date:

03 February 2020 (03.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/800,359 01 February 2019 (01.02.2019) US
62/891,925 26 August 2019 (26.08.2019) US

(71) Applicant: **NOVAROCK BIOTHERAPEUTICS, LTD.**
[US/US]; 801 South Princeton Corporate Center, Ewing
Township, NJ 08628 (US).

(72) Inventors: **LI, Han**; 1 Claire Dr, Newtown, PA 18940
(US). **LEI, Ming**; 20 Lockwood Dr, Princeton, NJ 08540
(US). **PEI, Yi**; 1836 Glenwood Dr, Paoli, PA 19301 (US).
HUANG, Haichun; 2425 Sueno Way, Fremont, CA 94539
(US).

(74) Agent: **WARREN, Lisa, M.**; Morse, Barnes-Brown &
Pendleton P.C., CityPoint, 480 Totten Pond Road, 4th Floor,
Waltham, MA 02451 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-CLAUDIN 18 ANTIBODIES AND METHODS OF USE THEREOF




FIG. 3A

(57) Abstract: Antibodies that specifically bind to the human tight junction molecule CLDN18.2 and have functional properties that make them suitable for use in antibody-based immunotherapies of a disease associated with aberrant expression of CLDN18.2 are disclosed.

[Continued on next page]

WO 2020/160560 A3

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

17 September 2020 (17.09.2020)